PTGS2 and urinary bladder carcinoma: We also examined the cell surface expression of E-cadherin, as an epithelial marker, and vimentin, as a mesenchymal marker, in the three bladder cancer cell lines treated with the three Cox-2 inhibitors using the FCM.